BCEL News

June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week.   Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more

Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week with losses. The stock closed Friday at $37.22, down 3.3% from the opening trade. With millions of users...read more

Atreca, a preclinical biotech developing immunotherapies for solid tumors, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Existing investors had indicated an interest in buying up to $60 million on the IPO (48% of the deal). Atreca plans to list on the Nasdaq under the symbol BCEL. Cowen, Evercore ISI and Stifel acted as...read more

A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch June/July IPOs as well. Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more